July 2008

Should metformin be used to prevent diabetes in high-risk patients?

September 02, 2008

Lipids

As outlined by the authors, use of metformin is an appealing option because it is safe, produces few side effects, and is a cost-effective way to target some of the defects known to contribute to the metabolic defects associated with diabetes.

The effect of diabetes on death and hospitalization in heart failure patients

September 02, 2008

Lipids

In the cohort study conducted by Ahmed and colleagues, the investigators assessed whether diabetes was associated with worse outcomes in heart failure regardless of the associated risk factors and comorbidities.

Warfarin versus aspirin for stroke prevention in the elderly study: Putting fears to rest

September 02, 2008

Lipids

The article by Mant and colleagues concerning the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study is a welcomed addition to the now vast literature regarding the relative benefits of warfarin anticoagulation in patients with atrial fibrillation.

Extreme lipoprotein(a) levels and myocardial infarction

September 02, 2008

Lipids

We conducted a study to determine whether high lipoprotein(a) levels predicted the risk of myocardial infarction (MI) and ischemic heart disease. Unlike other studies, we measured lipoprotein(a) levels shortly after sampling and corrected for regression dilution bias.

Lipoprotein(a) and coronary artery disease:

September 02, 2008

Lipids

The well-established causative role of low-density lipoprotein particles in atherosclerotic plaque development has led to this biomarker being a primary target of treatment in the prevention of coronary artery disease.

Diabetes-related poor outcomes in chronic heart failure: Complex interactions with sex and age

July 15, 2008

Lipids

This propensity-matched study, in which patients with and without diabetes were well balanced in all measured baseline characteristics, including traditional risk factors and comorbidities, found that diabetes was associated with increased mortality and hospitalization in ambulatory patients who had chronic, mild-to-moderate heart failure and were receiving angiotensin-converting enzyme inhibitors. These findings also highlight the sex- and age-related variations in the effect of diabetes in these patients.

A systematic review of metformin treatment in persons at risk for diabetes mellitus

July 06, 2008

Lipids

A recent meta-analysis of 31 randomized controlled trials with 4500 participants showed that metformin treatment significantly decreased weight, improved dyslipidemia and insulin resistance, and reduced the incidence of new-onset diabetes by 40%, with beneficial effects maintained over time. Further studies will show whether the metabolic improvements achieved with metformin treatment will ultimately result in a decrease in cardiovascular morbidity and mortality.